Therefore, we consider YG8R to be a suitable mouse model in which to investigate potential FRDA therapies and we now report the effects of prolonged treatment with HDAC inhibitors 106, 136 and 109. The gene discussed is HDAC9; the disease is Friedreich ataxia.